Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2014 08:51 ET | Source: Prima BioMed Ltd

Prima BioMed's CAN-002 CVac(TM) Trial Published in Journal for ImmunoTherapy of Cancer

SYDNEY, AUSTRALIA--(Marketwired - Jun 23, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today announced that a research article titled "A phase 2, single-arm study of...
June 19, 2014 08:19 ET | Source: Prima BioMed Ltd

Prima BioMed to Present at 2014 WAGO Annual Meeting

SYDNEY, AUSTRALIA--(Marketwired - Jun 19, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today advised that the Western Association of Gynecologic Oncologists (WAGO)...
June 01, 2014 19:38 ET | Source: Prima BioMed Ltd

CVAC Demonstrates Positive Trend in Overall Survival in Second Remission Ovarian Cancer

SYDNEY, AUSTRALIA--(Marketwired - Jun 1, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Interim overall survival data from CAN-003 clinical trial demonstrates...
May 30, 2014 08:16 ET | Source: Prima BioMed Ltd

Prima Biomed to Host Conference Call to Discuss Abstract Presented at ASCO on New Interim Overall Survival and Final Progression Free Survival Data for the Company's CAN-003 Trial

SYDNEY, AUSTRALIA--(Marketwired - May 30, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today advised that the Company will host a conference call and webcast...
May 25, 2014 21:21 ET | Source: Prima Biomed

Prima's CVac Patent Application Receives U.S. Notice of Allowance

SYDNEY, AUSTRALIA--(Marketwired - May 25, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") is pleased to announce that the Company has received a Notice of Allowance from...
May 14, 2014 18:00 ET | Source: Prima Biomed Ltd.

Prima BioMed's CVac Demonstrates Improvement in Progression-Free Survival in Second Remission Ovarian Cancer

SYDNEY, AUSTRALIA--(Marketwired - May 14, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Final PFS data from CAN-003 trial of CVac indicate stronger trends toward...
May 09, 2014 07:00 ET | Source: Prima BioMed Ltd

Prima BioMed's CVac(TM) Granted Fast Track Designation by FDA

SYDNEY, AUSTRALIA--(Marketwired - May 9, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") is pleased to announce today that the United States Food and Drug Administration ("FDA")...
April 29, 2014 09:52 ET | Source: Prima BioMed

Prima BioMed Third Quarter Conference Call

SYDNEY, AUSTRALIA--(Marketwired - Apr 29, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today released its Appendix 4C - Quarterly Report for...
April 28, 2014 09:31 ET | Source: Prima BioMed

Prima BioMed's CAN-004 Phase 2 Trial for CVac(TM) Commences Recruitment

SYDNEY, AUSTRALIA--(Marketwired - Apr 28, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") today announced that enrolment has commenced for its amended phase 2 CAN-004 clinical trial in...
April 06, 2014 21:30 ET | Source: Prima BioMed

Prima BioMed to Present at 13th Annual Needham Healthcare Conference

SYDNEY, AUSTRALIA--(Marketwired - Apr 6, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today announced that its Chief Executive Officer, Matthew Lehman, will present...